Invariant natural killer T cells coordinate removal of senescent cells
Failure of endogenous immune surveillance mechanisms to remove senescent cells drives the progression of diseases. The identity of the endogenous immune surveillance that mediated senescent cell clearance in vivo is not clear. This paper describes how lipid antigen presentation to activate iNKT cells can constitute an endogenous surveillance system that can be manipulated to clear senescent cells in disease models.
- Apr 2022
Harnessing endogenous immune biology to ablate pathogenic senescent cells and treat diseaseDeciduous CEO, Robin Mansukhani, is speaking at the Longevity Leaders World Congress in London this April. Tune in to hear the story of how we’ve identified an endogenous immune mechanism for clearing senescent cells, therapeutically harnessed the immune system to remove senescent cells in a diseased state, and achieved therapeutically relevant endpoints and durable effects.Read More
- Nov 2021
Eisai Innovation, Inc. and MBC BioLabs Announce Golden Ticket WinnerEisai Innovation, Inc. and MBC BioLabs are happy to announce Deciduous Therapeutics as the winner of their 2021 Golden Ticket Competition. Eisai Innovation, Inc.’s inaugural competition provides the winning company’s entrepreneurial scientists and emerging biotechnology start-up with lab space in the MBC BioLabs facility to pursue drug discovery and innovation for the potential future benefit ...Read More
- Oct 2021
Deciduous Therapeutics Announces Appointments to the Board, SAB, and Advisor RolesDeciduous Therapeutics, an early stage immune therapy start-up, announced today the appointment of an independent board member, additional Scientific Advisory Board members, and company advisors. Mr. Robert Forrester joins Deciduous as an Independent Board Member. He will be joining Robin Mansukhani, Deciduous’ Co-founder and CEO, Anil Bhushan, Scientific Founder of Deciduous, and Dylan Morris, Venture Partner at CRV. Mr. Forrester is ...Read More
- Oct 2021
Bakar Labs Awards Deciduous Therapeutics and Rubik Therapeutics 2021 Golden TicketsCompanies Can Access Free Lab Space and Facilities for a Year at UC Berkeley’s Flagship Bioscience Incubator BERKELEY, Calif., Oct. 21, 2021 /PRNewswire/ — Deciduous Therapeutics and Rubik Therapeutics have won 2021 Golden Tickets, granting the companies access to free lab space and facilities for a year, Bakar Labs announced today. The opportunity will give the ...Read More
Shedding Senescent Cells with Deciduous Therapeutics
Reawakened immune cells show promise in mice against zombie cells tied to diseases of aging
Can a rare immune cell offer the key to slowing down senescence? A Bay Area startup looks to find out
Harnessing the immune system to target cellular senescence
- Apr 2021
How Long Can We Live?In 1990, not long after Jean-Marie Robine and Michel Allard began conducting a nationwide study of French centenarians, one of their software programs spat out an error message. An individual in the study was marked as 115 years old, a number outside the program’s range of acceptable age values. They called their collaborators in Arles, ...
- Nov 2020
Send in the SenolyticsDespite early failures in the clinic, the idea of anti-aging therapies that purge the body of dying cells is gaining traction with a raft of startups now focused on senescence. Unity Biotechnology was one of the darlings of the nascent anti-aging biotech sector. With big-name investors, such as Jeff Bezos and Peter Thiel, an impressive lineup ...